These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 34934456)

  • 1. Pathological complete response following cisplatin or carboplatin-based neoadjuvant chemotherapy for triple-negative breast cancer: A systematic review and meta-analysis.
    Vidra R; Nemes A; Vidrean A; Pintea S; Tintari S; Deac A; Ciuleanu T
    Exp Ther Med; 2022 Jan; 23(1):91. PubMed ID: 34934456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis.
    Petrelli F; Coinu A; Borgonovo K; Cabiddu M; Ghilardi M; Lonati V; Barni S
    Breast Cancer Res Treat; 2014 Apr; 144(2):223-32. PubMed ID: 24557340
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRCA Mutation Status in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Pivotal Role for Treatment Decision-Making.
    Pavese F; Capoluongo ED; Muratore M; Minucci A; Santonocito C; Fuso P; Concolino P; Di Stasio E; Carbognin L; Tiberi G; Garganese G; Corrado G; Di Leone A; Generali D; Fragomeni SM; D'Angelo T; Franceschini G; Masetti R; Fabi A; Mulè A; Santoro A; Belli P; Tortora G; Scambia G; Paris I
    Cancers (Basel); 2022 Sep; 14(19):. PubMed ID: 36230495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Platinum dose in neoadjuvant therapy for triple-negative breast cancer: A systematic review and network meta-analysis.
    Petrelli F; Ghidini A; Rea C; Parati MC; Borgonovo K; Ghidini M; Ruatta F; Zaniboni A; Luciani A; Garrone O; Tomasello G
    Curr Probl Cancer; 2024 Jun; 50():101096. PubMed ID: 38608530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review.
    Pandy JGP; Balolong-Garcia JC; Cruz-Ordinario MVB; Que FVF
    BMC Cancer; 2019 Nov; 19(1):1065. PubMed ID: 31703646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis.
    Poggio F; Bruzzone M; Ceppi M; Pondé NF; La Valle G; Del Mastro L; de Azambuja E; Lambertini M
    Ann Oncol; 2018 Jul; 29(7):1497-1508. PubMed ID: 29873695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of platinum-based and non-platinum-based drugs on triple-negative breast cancer: meta-analysis.
    Lin C; Cui J; Peng Z; Qian K; Wu R; Cheng Y; Yin W
    Eur J Med Res; 2022 Oct; 27(1):201. PubMed ID: 36242046
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of neoadjuvant platinum-based chemotherapy in
    Caramelo O; Silva C; Caramelo F; Frutuoso C; Almeida-Santos T
    Hered Cancer Clin Pract; 2019; 17():11. PubMed ID: 30962858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome for triple negative breast cancer in a retrospective cohort with an emphasis on response to platinum-based neoadjuvant therapy.
    Walsh EM; Shalaby A; O'Loughlin M; Keane N; Webber MJ; Kerin MJ; Keane MM; Glynn SA; Callagy GM
    Breast Cancer Res Treat; 2019 Feb; 174(1):1-13. PubMed ID: 30488345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platinum-based neoadjuvant chemotherapy for triple-negative breast cancer: a systematic review and meta-analysis.
    Li ZY; Zhang Z; Cao XZ; Feng Y; Ren SS
    J Int Med Res; 2020 Oct; 48(10):300060520964340. PubMed ID: 33100072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A meta-analysis of platinum-based neoadjuvant chemotherapy versus standard neoadjuvant chemotherapy for triple-negative breast cancer.
    Wang D; Feng J; Xu B
    Future Oncol; 2019 Aug; 15(23):2779-2790. PubMed ID: 31293180
    [No Abstract]   [Full Text] [Related]  

  • 12. Platinum-Based Neoadjuvant Chemotherapy for Breast Cancer With BRCA Mutations: A Meta-Analysis.
    Wang CJ; Xu Y; Lin Y; Zhu HJ; Zhou YD; Mao F; Zhang XH; Huang X; Zhong Y; Sun Q; Li CG
    Front Oncol; 2020; 10():592998. PubMed ID: 33304851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cisplatin versus carboplatin in combination with paclitaxel as neoadjuvant regimen for triple negative breast cancer.
    Huang L; Liu Q; Chen S; Shao Z
    Onco Targets Ther; 2017; 10():5739-5744. PubMed ID: 29238206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of different neoadjuvant treatment regimens in BRCA-mutated triple negative breast cancer: a systematic review and meta-analysis.
    Caramelo O; Silva C; Caramelo F; Frutuoso C; Pinto L; Almeida-Santos T
    Hered Cancer Clin Pract; 2022 Sep; 20(1):34. PubMed ID: 36085046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of tolerability and efficacy of incorporating carboplatin in neoadjuvant anthracycline and taxane based therapy in a BRCA1 enriched triple-negative breast cancer cohort.
    Sella T; Gal Yam EN; Levanon K; Rotenberg TS; Gadot M; Kuchuk I; Molho RB; Itai A; Modiano TM; Gold R; Kaufman B; Shimon SP
    Breast; 2018 Aug; 40():141-146. PubMed ID: 29800932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Homologous Recombination Deficiency (HRD) and BRCA 1/2 Gene Mutation for Predicting the Effect of Platinum-Based Neoadjuvant Chemotherapy of Early-Stage Triple-Negative Breast Cancer (TNBC): A Systematic Review and Meta-Analysis.
    Chai Y; Chen Y; Zhang D; Wei Y; Li Z; Li Q; Xu B
    J Pers Med; 2022 Feb; 12(2):. PubMed ID: 35207810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. qRT-PCR-based DNA homologous recombination-associated 4-gene score predicts pathologic complete response to platinum-based neoadjuvant chemotherapy in triple-negative breast cancer.
    Zuo K; Yuan X; Liang X; Sun X; Liu S; Connell PP; Li X; Yang W
    Breast Cancer Res Treat; 2022 Jan; 191(2):335-344. PubMed ID: 34797456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant Chemotherapy of Triple-Negative Breast Cancer: Evaluation of Early Clinical Response, Pathological Complete Response Rates, and Addition of Platinum Salts Benefit Based on Real-World Evidence.
    Holanek M; Selingerova I; Bilek O; Kazda T; Fabian P; Foretova L; Zvarikova M; Obermannova R; Kolouskova I; Coufal O; Petrakova K; Svoboda M; Poprach A
    Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33808149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Platinums in Triple-Negative Breast Cancer.
    Lynce F; Nunes R
    Curr Oncol Rep; 2021 Mar; 23(5):50. PubMed ID: 33754211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platinum agents in the treatment of early-stage triple-negative breast cancer: is it time to change practice?
    Agrawal LS; Mayer IA
    Clin Adv Hematol Oncol; 2014 Oct; 12(10):654-8. PubMed ID: 25658890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.